酪酸梭菌二联活菌散联合头孢哌酮钠舒巴坦钠治疗肝硬化并发自发性腹膜炎的疗效以及安全评估

The clinical effect and safety of clostridium butyricum viable powder combined with cefoperazone sodium and Sulbactam Sodium in treatment of liver cirrhosis patients complicated with spontaneous bacterial peritonitis

[目的]观察酪酸梭菌二联活菌散联合头孢哌酮钠舒巴坦钠对肝硬化并发自发性腹膜炎患者的临床疗效以及安全评估。[方法]选择2015年3月~2017年1月我院治疗的自发性细菌性腹膜炎肝硬化患者108例。使用信封法将患者随机分为对照组和观察组,每组54例。对照组使用头孢哌酮钠舒巴坦钠,1.5g静脉滴注,1次/12h,14d为1疗程;观察组在对照基础上加用酪酸梭菌二联活菌散3袋/次,2次/d,14d为1疗程。ELISA法检测患者治疗前后血清炎性因子IL-6和TNF-α的变化。比较2组临床疗效和不良反应。[结果]治疗前2组IL-6和TNF-α表达差异无统计学意义(P>0.05),但治疗后观察组IL-6和TNF-α表达显著低于对照组(P<0.01)。观察组临床治疗有效率为88.9%(48/54),显著高于对照组的74.1%(40/54)(P<0.05)。观察组不良反应发生率为9.3%(5/54),对照组不良反应发生率为11.1%(6/54),2组差异无统计学意义(P>0.05)。[结论]酪酸梭菌二联活菌散联合头孢哌酮钠舒巴坦钠可以显著抑制肝硬化并发自发性腹膜炎患者的炎症反应,临床疗效显著,使用安全。

[Objective]To detect the clinical effect and safety of clostridium butyricum viable powder combined with cefoperazone sodium and sulbactam sodium in treatment of liver cirrhosis patients complicated with spontaneous bacterial peritonitis（SBP）.[Methods]A total of 108 liver cirrhosis complicated with SBP patients were enrolled in this study.The patients were randomly divided into control group and observation group,with 54 cases in each group.The control group was given cefoperazone sodium and sulbactam sodium（1.5g intravenous drip,1times/12 h,14dfor a course of treatment）;the observation group based on control group was given clostridium butyricum two joint viable powder（3bag/time,2times/d,14 dfor a course of treatment）.IL-6and TNF-α were detected by ELISA before and after treatment in each group.The clinical efficacy and adverse reactions were compared between the two groups.[Results]There were no significant difference between IL-6and TNF-αin the two groups before treatment（P〉0.05）.But after treatment,IL-6and TNF-αin the observation group were significantly lower than those in the control group（P〈0.01）.The clinical effective rate in observation group was 88.9%（48/54）,which was signifi-cantly higher than that of 74.1%（40/54）in control group（P〈0.05）.The incidence of adverse reactions was 9.3%（5/54）in observation group and 11.1%（6/54）in the control group.There was no significant difference between the two groups（P〈0.05）.[Conclusion]Clostridium butyricum viable powder combined with cefoperazone sodium and sulbactam sodium can significantly inhibit inflammatory response in liver cirrhosis complicated with SBP patients,with significant clinical efficacy and safety.